Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Edema Clear all
Completed Phase 4 Interventional Results available

Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium

NCT01573572
View directory record Official record
Conditions
Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
pegaptanib sodium injection
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
50 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
4
States / cities
Murrieta, California • Marshalltown, Iowa • West Mifflin, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Jul 22, 2026, 5:54 AM EDT
Not listed Phase 1Phase 2 Interventional

Management of Volume Overload HF Patients by Individual DSR Treatment adJustment-a clinicAl inVestigation of InfusatE2.0

NCT05965934
View directory record Official record
Conditions
Heart Failure, Volume Overload
Interventions
Direct Sodium Removal Infusate 2.0
Drug
Lead sponsor
Sequana Medical N.V.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Jul 22, 2026, 5:54 AM EDT
Active, not recruiting Phase 3 Interventional

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)

NCT06625398
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
VRDN-003, Placebo
Drug
Lead sponsor
Viridian Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
37
States / cities
Scottsdale, Arizona • Canoga Park, California • Huntington Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 22, 2026, 5:54 AM EDT
Completed No phase listed Observational Results available

Safety and Feasibility of Prima-Temp Thermometer Patch

NCT01587014
View directory record Official record
Conditions
Erythema, Edema, Papules White, Eruption
Interventions
Not listed
Lead sponsor
Poudre Valley Health System
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Loveland, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 19, 2017 · Synced Jul 22, 2026, 5:54 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol®) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia

NCT01451411
View directory record Official record
Conditions
Hyponatremia
Interventions
Conivaptan hydrochloride, Placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
2 Years to 17 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Jul 22, 2026, 5:54 AM EDT
Completed No phase listed Observational

Retrospective Study of the Safety and Efficacy of Patients With RVO in Subjects Who Completed Parent Study CLS1003-201

NCT02956330
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
Not listed
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2019 · Synced Jul 22, 2026, 5:54 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)

NCT01027650
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
AGN208397 intravitreal injection, dexamethasone intravitreal implant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Jul 22, 2026, 5:54 AM EDT
Not yet recruiting Not applicable Interventional

Evaluating the Use of Prehospital Lung Ultrasound in EMS: A Multicenter Pilot Study

NCT07549334
View directory record Official record
Conditions
Congestive Heart Failure(CHF), Pulmonary Edema
Interventions
Pulmonary ultrasound
Diagnostic Test
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Newark, Delaware • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 22, 2026, 5:54 AM EDT
Completed Not applicable Interventional Results available

Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery

NCT01847638
View directory record Official record
Conditions
Cataract, Retinal Edema, Inflammation
Interventions
Prolensa (bromfenac 0.07%), Ilevro (nepafenac 0.3%)
Drug
Lead sponsor
Melissa Toyos
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Jul 22, 2026, 5:54 AM EDT
Not listed No phase listed Observational

Iluvien Registry Safety Study

NCT01998412
View directory record Official record
Conditions
Chronic Diabetic Macular Oedema Considered Insufficiently Responsive to Available Therapies
Interventions
Not listed
Lead sponsor
Alimera Sciences
Industry
Eligibility
Not listed
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Jul 22, 2026, 5:54 AM EDT
Completed Phase 2 Interventional Results available

Histamine Glutamate Antagonism in Stroke

NCT02142712
View directory record Official record
Conditions
Acute Cerebrovascular Accident, Cerebral Edema
Interventions
Diphenhydramine, Pantoprazole, Famotidine, Dextromethorphan
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Jul 22, 2026, 5:54 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy & Safety for 3 Infusion Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia

NCT00478192
View directory record Official record
Conditions
Hyponatremia
Interventions
Conivaptan, Placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
21
States / cities
Huntsville, Alabama • Tucson, Arizona • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Jul 22, 2026, 5:54 AM EDT
Completed Phase 3 Interventional Results available

Treatment for CI-DME in Eyes With Very Good VA Study

NCT01909791
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Prompt Laser, Prompt aflibercept, Deferred laser, Deferred aflibercept
Procedure · Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
100
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 84 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Jul 22, 2026, 5:54 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Sirolimus to Treat Diabetic Macular Edema

NCT00711490
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Sirolimus
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Jul 22, 2026, 5:54 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Ozurdex for Combined Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema After Cataract Surgery

NCT01284478
View directory record Official record
Conditions
Pseudophakic Cystoid Macular Edema,, Diabetic Macular Edema
Interventions
Dexamethasone Implant
Drug
Lead sponsor
Northern California Retina Vitreous Associates
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Jul 22, 2026, 5:54 AM EDT
Recruiting Not applicable Interventional

The HEARTFELT Study

NCT06222099
View directory record Official record
Conditions
Heart Failure, Chronic Heart Failure
Interventions
Heartfelt Device installed, Standard care, Heartfelt-guided care, Questionnaires
Device · Other
Lead sponsor
Heartfelt Technologies
Industry
Eligibility
22 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Little Rock, Arkansas • Hackensack, New Jersey • Bala-Cynwyd, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 22, 2026, 5:54 AM EDT
Completed Not applicable Interventional Results available

Cochlear Implantation After Labyrinthectomy or a Translabyrinthine Surgical Approach

NCT02309099
View directory record Official record
Conditions
Unilateral Acoustic Neuroma, Meniere's Disease
Interventions
Cochlear Implant
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 6, 2019 · Synced Jul 22, 2026, 5:54 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Acetazolamide on Subclinical High-Altitude Pulmonary Edema Detected by Lung Ultrasonography

NCT03490916
View directory record Official record
Conditions
High Altitude Pulmonary Edema
Interventions
Acetazolamide, Placebo
Drug
Lead sponsor
Vincent Kan
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Jul 22, 2026, 5:54 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety of THR-149 in Subjects With Diabetic Macular Edema (DME)

NCT03511898
View directory record Official record
Conditions
Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
Interventions
THR-149 dose level 1, THR-149 dose level 2, THR-149 dose level 3
Drug
Lead sponsor
ThromboGenics
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Phoenix, Arizona • Boston, Massachusetts • Reno, Nevada + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Jul 22, 2026, 5:54 AM EDT
Enrolling by invitation No phase listed Observational

Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy

NCT05296447
View directory record Official record
Conditions
Diabetic Retinopathy, DR
Interventions
No Intervention
Other
Lead sponsor
AbbVie
Industry
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
19
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Jul 22, 2026, 5:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Energy-Based Lower Eyelid Rejuvenation - Proof of Concept for InMode AccuTite With or Without Morpheus8

NCT04103619
View directory record Official record
Conditions
Periorbital Edema
Interventions
AccuTite, AccuTite + Morpheus 8
Device
Lead sponsor
InMode MD Ltd.
Industry
Eligibility
29 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Sarasota, Florida • Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 9, 2022 · Synced Jul 22, 2026, 5:54 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Oral Minocycline in Treating Bilateral Cystoid Macular Edema Associated With Retinitis Pigmentosa

NCT02140164
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Minocycline
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
12 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Jul 22, 2026, 5:54 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)

NCT06491914
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema
Interventions
Aflibercept 8 mg
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
53
States / cities
Arcadia, California • Bakersfield, California • Beverly Hills, California + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jul 22, 2026, 5:54 AM EDT
Recruiting Phase 2 Interventional

A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO

NCT07205887
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
Interventions
EYE103, Aflibercept 2.0 mg
Drug
Lead sponsor
EyeBiotech Ltd.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
49
States / cities
Scottsdale, Arizona • Glendale, California • Modesto, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 22, 2026, 5:54 AM EDT